secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000950170-25-099389
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance
--------------------------------------------------------------------------------

- Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
- GAAP EPS $0.26 vs $0.10; adjusted EPS $0.37 vs $0.40.
- Orders grew >20% YoY and sequentially, 8th consecutive quarter of orders exceeding non-COVID revenue.
- Raises FY2025 revenue guidance to $715-$735M, organic non-COVID growth 12.5%-15.5%.
- All franchises grew YoY; consumables >20%, biopharma +20%, all geographies mid-teens.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/0000950170-25-099389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/rgen-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer